Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India

Ananya Chakraborty¹, Nishith Reval¹, Latha Kamath¹

1. Pharmacology and Therapeutics, Vydehi Institute of Medical Sciences and Research Centre, Bangalore, IND

Corresponding author: Ananya Chakraborty, dr_ananya@yahoo.com

Abstract

Background

Vaccination has provided a ray of hope in combating the coronavirus disease 2019 (COVID-19). Vaccines were rolled out as an emergency measure, with an expedited approval process. The available clinical trial data reveals the fact that vaccines mostly produce mild adverse events following immunization (AEFIs). Since the experiences are relatively new, it is important to monitor safety in a real-world setting. With this background, this survey was conducted.

Methods

This cross-sectional study was approved by the institutional ethics committee (IEC) of Vydehi Institute of Medical Sciences and Research Centre. This was conducted over a period of four months at select apartment complexes around Whitefield, Bangalore. The participants were invited to fill up data through online Google Forms (Google, Mountain View, CA, USA). They were requested to provide demographic details, information related to vaccination, and AEFIs. Eligibility to participate included recipients of vaccines who received Emergency Use Authorization (EUA) in India. Data were analyzed using SPSS version 20.00 (IBM Corporation, Armonk, NY, USA).

Results

The total number of participants in the study was 322. Out of this, 37.6% (121) were males and 62.4% (201) were females. The mean age of the participants was 34.9 ± 12.4 (mean ± standard deviation (SD) years. About 30% (96) of the study participants had comorbidities. Overall, 67.4% (217) of the participants suffered from AEFI. Of them, immediate reactions were reported by 18.3% (59) and 10.2% (32) of the participants after the first and second doses, respectively. A total of 0.9% (3) of the participants had immediate allergic reactions. The most common local and systemic AEFIs were pain at the injection site and extreme tiredness. AEFIs were found to be mild and with a probable association with vaccination as per the WHO scale. The number of females experiencing AEFIs was found to be higher when compared with males for both local and systemic reactions. There was a statistically significant increase in the number of individuals experiencing general adverse effects following the first dose of Covishield™ (Serum Institute of India Private Limited, Pune, India) when compared with Covaxin™ (Bharat Biotech Limited, Hyderabad, India) (P < 0.05). Of the participants, 5.9% (19) were diagnosed with COVID-19 post-vaccination. Among them, 15.8% (3) required hospitalization, with 10.5% (2) of them requiring an oxygen bed. It was observed that 76.5% (166) of the participants did not report their reactions to concerned authorities.

Conclusion

Based on our sample, the study reflects that COVID-19 vaccination causes mild AEFI in most vaccine recipients. It also provides an insight that reporting of AEFIs is very low. It is, therefore, important to take up more awareness campaigns about reporting of AEFIs through the COVID Vaccine Intelligence Network (CoWIN) portal.

Introduction

Adverse events following immunization (AEFIs) are defined as any untoward medical occurrence that follows immunization and that does not necessarily have a causal relationship with the usage of a vaccine. The adverse event may be any unfavorable or unintended sign, abnormal laboratory finding, symptom, or disease [1]. In India, two coronavirus vaccines received Emergency Use Authorization (EUA) on January 3, 2021. These were Covishield™ (AstraZeneca’s vaccine manufactured by Serum Institute of India Private Limited, Pune, India) and Covaxin™ (Bharat Biotech Limited, Hyderabad, India). The vaccines were in phase III clinical trials [2,3].

How to cite this article

Chakraborty A, Reval N, Kamath L (February 01, 2022) Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India. Cureus 14(2): e21809. DOI 10.7759/cureus.21809
Initially, in the first phase, the country vaccinated people at the highest risk of exposure, such as healthcare and frontline workers, on priority with Covishield™, and then, Covaxin™ was made available. From March 2021, the second phase of vaccination was started. Vaccines were available first for people aged above 60 and above 45 with comorbidities. This was expanded on April 1, 2021, to cover everyone above 45 years. In the third phase, vaccines were made available for people above 18 years of age. The vaccination program started at the immunization clinics at hospitals, followed by vaccination drives hosted at outreach sites. The guideline document released by the Government of India mentioned management plans for AEFI and recording of the same through the COVID Vaccine Intelligence Network (CoWIN) software [4].

There were circulars issued by the Pharmacovigilance Program of India (PvPI) to the adverse drug reaction monitoring centers (AMCs) to actively monitor and report coronavirus disease 2019 (COVID-19) vaccine-related AEFIs. The guideline suggested that the AEFIs need to be updated through VigiFlow®. For nonserious reactions, the same should be reported by filling up the suspected Adverse Drug Reaction (ADR) reporting form through VigiFlow®. Serious ones need to be updated through ADR forms to PvPI through VigiFlow®, as well as to the National Coordination Center (NCC)-PvPI by email after filling up the AEFI notification form. AMCs were also directed to report the cases to the District Immunization Officer or State Expanded Program of Immunization Officer [5-7].

The WHO COVID vaccine safety surveillance manual recommends active and various passive systems to monitor AEFIs. This is to ensure vaccine safety and generate data on the overall short-term and long-term effects [8]. Previous systematic reviews and studies conducted mostly on healthcare workers and published reports on the active surveillance of spontaneous reports by AMCs pointed toward the fact that COVID-19 vaccines are relatively safe. The studies stressed the need for population-based surveillance and a long-term follow-up especially in vaccinated individuals with comorbidities [7,9-15].

With this background, this cross-sectional survey was taken up to assess the self-reported AEFIs of COVID-19 vaccines in select apartment complexes in and around Whitefield, Bangalore, India.

Materials And Methods

It was a cross-sectional, questionnaire-based online survey. It was conducted over a period of four months between July 2021 and October 2021. It was approved by the institutional ethics committee of Vydehi Institute of Medical Sciences and Research Centre, with reference number VIEC/2021/APP/009.

Confidentiality was ensured so that only authorized persons had access to the data. The study tool was a Google form questionnaire that was distributed to the residents via emails through the managing committees of the apartment complexes and personal messages through known contacts. The inclusion criteria were vaccinated residents of large apartment complexes who received at least one dose of vaccine that was approved by regulatory authorities in India. The Google form had an introductory section explaining the study and an option to indicate consent. The exclusion criteria included those who received vaccines not approved in India (nonresident Indians) and those who were unaware of the type of vaccine they received. The questionnaire was constructed based on a modified version of the screening questionnaire for adult immunization [16]. The questionnaire included personal information on the respondent’s demographic characteristics, general information related to the COVID-19 vaccine, the type of vaccine received, the number of doses, AEFIs, and health status in terms of medications taken, comorbidity, and details on AEFI reporting. The AEFIs were subjected to causality assessment as per the WHO scale [17].

A pilot survey with 20 participants was first conducted for the purpose of calculating the sample size. It was found that 70% (14) of the vaccinated individuals had AEFIs. Considering the confidence interval at 95%, precision at 5%, and prevalence at 70%, the minimum recommended sample size was derived at 320 (N = 320). It was decided to close the questionnaire link once the desired sample size was achieved.

Baseline data were assessed using descriptive statistics. All quantitative variables are presented as means and standard deviations, and all qualitative variables are presented as frequencies and percentages. For the comparison of categorical variables, the chi-square test was used. Data were entered into Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) and analyzed using SPSS version 20.00 (IBM Corporation, Armonk, NY, USA).

Results

Demographic characteristics

The total number of participants in the study was 322. Of the 322 participants, 37.6% (121) were males and 62.4% (201) were females. The mean age of the participants was 34.9 ± 12.4 (mean ± SD) years. Of the participants, 3.4% (11) were senior citizens (60 years or above) who participated in the study. Of the participants, 39.8% (128) were between 18 and 30 years, 28.6% (92) were between 31 and 40 years, 23.3% (75) were between 41 and 50 years, and 4.9% (16) were between 51 and 60 years. The mean BMI was 25.2 ± 4.4 (mean ± SD) kg/m². Regarding professional status, 67.7% (218) were non-frontline workers and 32.3% (104) were frontline workers. Of the participants, 96.5% (311) completed both doses, and 3.5% (11) of them completed only one dose of vaccine. The results are presented in Table 1.
Comorbidities
About 30% (96) of the study participants had comorbidities. Around 10% (25) of them were found to have diabetes, 11.2% (36) have hypertension, 3.1% (10) have a thyroid disorder, 0.9% (3) have respiratory disorders, and 0.3% (1) had hypersensitivity reactions to COVID-19 vaccination. The detailed list and frequency of the comorbidities are presented in Table 1.

Type of vaccine
Of the participants, 77.9% (251) received Covishield™ and 22.1% (71) received Covaxin™. The details are shown in Table 1.

Vaccination site
Of the participants, 65.2% (210) received the shot at hospitals, 14.3% (46) at their apartment complex vaccination drives, 13.6% (44) at drives coordinated at workplaces, 0.9% (3) at primary health centers (PHCs), 0.3% (1) at church complexes, and the remaining 5.5% (18) at other sites such as Bruhat Bengaluru Mahanagara Palike (BBMP) office and community halls of residential areas.

Diagnosis of COVID-19 post-vaccination
During the study duration, 5.9% (19) of the participants were diagnosed with COVID-19 post-vaccination. Among them, 15.8% (3) required hospitalization, with 10.5% (2) of them requiring oxygen. The results are shown in Table 1.
| Variables                  | Outcome                          | Percentage | Frequency |
|----------------------------|----------------------------------|------------|-----------|
| Gender                     | Male                             | 37.6%      | 121       |
|                            | Female                           | 62.4%      | 201       |
| Age (years)                | 18–30                            | 39.8%      | 128       |
|                            | 31–40                            | 28.6%      | 92        |
|                            | 41–50                            | 23.3%      | 75        |
|                            | 51–60                            | 5%         | 16        |
|                            | >60                              | 3.4%       | 11        |
| Age (years) (mean ± SD)    | 34.9 ± 12.4                      |            |           |
| BMI (kg/m²) (mean ± SD)    | 25.2 ± 4.4                       |            |           |
| Frontline worker           | No                               | 67.7%      | 218       |
|                            | Yes, I work in the healthcare sector | 28%     | 90        |
|                            | Yes, I work in a non-healthcare sector | 4.3%    | 14        |
| Comorbidities              | Diabetes                         | 10%        | 25        |
|                            | Hypertension                     | 11.2%      | 36        |
|                            | Thyroid disorder                 | 3.1%       | 10        |
|                            | Respiratory disorder             | 0.9%       | 3         |
|                            | Hypersensitivity                 | 0.3%       | 1         |
|                            | Psoriasis                        | 0.3%       | 1         |
| Type of vaccine            | Covishield™                      | 77.9%      | 251       |
|                            | Covaxin™                         | 22.1%      | 71        |
| Vaccine site               | Hospital                         | 65.2%      | 210       |
|                            | Apartment complex drive          | 14.3%      | 46        |
|                            | Workplace                        | 13.7%      | 44        |
|                            | BBMP, government setup community halls of residential areas | 5.6%  | 18        |
|                            | PHC                              | 0.9%       | 3         |
|                            | Church complex                   | 0.3%       | 1         |
| Diagnosis of COVID-19      | Post-vaccination                 | 5.9%       | 19        |

**TABLE 1: Demographic and vaccination details**

**AEFI**

Overall, 67.4% (217) of the participants suffered from AEFI. Of them, immediate reactions within 30 minutes of the vaccine were reported by 18.3% (59) and 10.2% (32) of the participants after the first and second doses, respectively. The most common reactions were extreme tiredness, followed by pain at the injection site. A total of 0.9% (3) of the participants had immediate allergic reactions.

Of the total participants, 63.6% (204) had local reactions following the first dose, and 46.3% (144) had local reactions following the second dose. The most common local reaction was pain, followed by swelling and weakness of the arm. Systemic reactions were reported by 71.4% (230) and 48.5% (151) of the participants, respectively, following the first and second doses. The most common systemic reaction was generalized weakness, followed by fever, headache, chills, dizziness, somnolence, and loss of appetite. The AEFIs included gastrointestinal disorders (nausea, vomiting, decrease in appetite, and pain in the abdomen),

2022 Chakraborty et al. Cureus 14(2): e21809. DOI 10.7759/cureus.21809
nervous system disorders (headache, dizziness, somnolence, and insomnia), skin and subcutaneous tissue disorders (urticaria, hair fall, and rash), musculoskeletal and connective tissue disorders (body pain and pain in extremity), and general and administration site disorders (injection site pain, fever, heaviness, swelling, and tingling). The types of local and systemic reactions with prevalence following the first and second doses are presented in Table 2.

| AEFIs                             | First dose (N = 322) | Second dose (N = 311) |
|-----------------------------------|----------------------|-----------------------|
|                                   | Percentage | Frequency | Percentage | Frequency  |
| Immediate reactions               |            |           |            |           |
| Overall                           | 18.3%      | 59        | 10.2%      | 32        |
| Extreme tiredness                 | 11.8%      | 38        | 6.4%       | 20        |
| Pain at the injection site        | 14.3%      | 46        | 6.8%       | 21        |
| Facial swelling                   | 0.6%       | 2         | 0.3%       | 1         |
| Dizziness/vertigo                 | 0.3%       | 1         | 1.6%       | 5         |
| Generalized severe itching/urticaria | 0.3%   | 1         | 0.6%       | 2         |
| Tingling in the left hand and cheek | 0.3%  | 1         | -          | -         |
| Fever                             | 0.3%       | 1         | 2.9%       | 9         |
| Headache                          | 0.3%       | 1         | -          | -         |
| Local reactions                   |            |           |            |           |
| Overall                           | 63.6%      | 204       | 46.3%      | 144       |
| Pain                              | 59%        | 190       | 41.6%      | 130       |
| Swelling                          | 12.4%      | 40        | 6.1%       | 19        |
| Weakness                          | 9%         | 29        | 5.4%       | 17        |
| Redness                           | 6.2%       | 20        | 3.5%       | 11        |
| Hard lump                         | 5.3%       | 17        | 2.9%       | 9         |
| Fever                             | 0.9%       | 3         | 1.6%       | 5         |
| Heaviness in the injected arm     | 0.6%       | 2         | 0.6%       | 2         |
| Urticaria/skin problem            | 0.3%       | 1         | 0.3%       | 1         |
| Koebner phenomenon                | 0.3%       | 1         | -          | -         |
| Systemic reactions                |            |           |            |           |
| Overall                           | 71.4%      | 230       | 48.5%      | 151       |
| Feeling tired/generalized weakness| 46.6%      | 150       | 31.5%      | 98        |
| Fever                             | 43.4%      | 140       | 19.9%      | 62        |
| Headache                          | 22.4%      | 72        | 21.2%      | 32        |
| Chills                            | 21.7%      | 70        | 17.9%      | 27        |
| Dizziness                         | 8.4%       | 27        | 5.9%       | 9         |
| Somnolence                        | 6.8%       | 22        | 7.9%       | 12        |
| Decrease in appetite              | 4.7%       | 15        | 2.6%       | 4         |
| Nausea                            | 2.5%       | 8         | 2.6%       | 4         |
| Insomnia                          | 1.9%       | 6         | 1.3%       | 2         |
| Runny nose                        | 1.6%       | 5         | 1.3%       | 2         |
| Cough                             | 1.2%       | 4         | 1.3%       | 2         |
| Side Effect                | First Dose | Second Dose |
|--------------------------|------------|-------------|
| Vomiting                 | 1.2%       | 0.7%        |
| Sore throat              | 1.2%       | 1.9%        |
| Abdominal pain           | 0.6%       | 1.9%        |
| Rash                     | 0.6%       | 0.7%        |
| Body pain                | 0.3%       | -           |
| Leg pain and shoulder pain| 0.3%       | -           |
| Discomfort               | 0.3%       | -           |
| Heavy menstruation       | 0.3%       | 0.7%        |
| Skin problem             | 0.3%       | 0.7%        |
| Severe hair fall         | 0.3%       | -           |

**TABLE 2: Details of AEFIs**

**Association of AEFI with gender, BMI, and types of vaccine**

The number of females experiencing AEFI was found to be higher when compared with males for both local and systemic reactions. The difference was, however, not statistically significant. There was no correlation between BMI and the total number of adverse events ($R$ value = 0.07). The number of participants experiencing local and systemic reactions following the first dose was higher with Covishield™ when compared with Covaxin™. There was a statistically significant increase in the number of individuals experiencing general adverse effects following the first dose of Covishield™ when compared with Covaxin™. There was no statistically significant difference in the number of participants experiencing local and systemic reactions following the second dose. The results are shown in Table 3.

| Association of AEFI | AEFI following the first dose | AEFI following the second dose |
|---------------------|-------------------------------|-------------------------------|
| Gender              |                               |                               |
| Male                | Yes 70                        | Yes 48                        |
|                     | No 51                         | No 69                         |
| Female              | Yes 134                       | Yes 96                        |
|                     | No 67                         | No 98                         |
| Type of vaccine     |                               |                               |
| Covishield™         | Yes 170                       | Yes 111                       |
|                     | No 81                         | No 132                        |
| Covaxin™            | 0.06 ($X^2 = 3.45$)           | 0.17 ($X^2 = 0.68$)           |
|                      |                               |                               |
| Systemic reactions  |                               |                               |
| Gender              |                               |                               |
| Male                | Yes 81                        | Yes 55                        |
|                     | No 40                         | No 62                         |
| Female              | Yes 150                       | Yes 97                        |
|                     | No 51                         | No 97                         |
| Type of vaccine     |                               |                               |
| Covishield™         | Yes 186                       | Yes 115                       |
|                     | No 63                         | No 128                        |
| Covaxin™            | 0.02 * ($X^2 = 5.81$)         | 0.29 ($X^2 = 1.14$)           |

**TABLE 3: Association of AEFI with gender and type of vaccine**

* denotes statistically significant difference.

**Pharmacotherapy for AEFI**

Of the participants, 71% (154) who experienced AEFI used tablet paracetamol (500/650 mg), and 1.8% (4) used other medications including herbal products, ice packs, antibiotics for hard lump, and mometasone.
Reporting of AEFI and causality analysis

Out of 67.4% (217) of participants who had AEFI, 19.8% (43) reported to the doctor, 3.7% (8) reported to PvPI, and 76.5% (166) mentioned that they did not report their reaction. All AEFIs were analyzed using the WHO-Uppsala Monitoring Centre (UMC) scale. They were found to have a probable association with vaccination. None were serious requiring hospitalization.

Discussion

In this study, we aimed to analyze COVID-19 vaccination safety in a select population of Bangalore, India. The participants belonged to apartment complexes located within a 10 km radius of the institution. This was the criteria laid down by the ethics committee, with the idea of monitoring the population who might have received vaccination at the institution and around Whitefield area. This may be also because the adverse drug reaction monitoring center (AMC and PvPI) that functions from the institution supports the nearby peripheral hospitals toward routing their ADR/AEFI to PvPI. The population was targeted toward apartment complexes as request could be forwarded through the MCs, and data could be generated outside the functionality of the hospital. Also, previous studies were conducted mostly on healthcare workers and from AMCs in India [7,10].

The survey was conducted through validated questionnaire uploaded at Google Forms. Participation was voluntary. All information was mandatory; only after responding to a question could the respondents move on to the next. The participants could respond to further questions only if they selected option for vaccine as Covaxin™ or Covishield™. This ensured no incomplete responses. It also ensured that the study is conducted on COVID–19 vaccines that received EUA in India. The responses were disabled once the target sample size was reached.

The COVID-19 vaccination drives in India were arranged at various sites. The participants of this study reside in apartment complexes. They received their vaccines at various sites, such as hospitals, apartment complexes, primary health centers, workplaces, community centers, and church complexes. Among the respondents, 57.6% (121) were males and 62.4% (201) were females. The mean age of the participants was 34.9 ± 12.4. The mean BMI was 25.2 ± 4.4 (mean ± SD) kg/m². The majority of the participants were between 18 and 30 years. The results coincide with previous studies where majority participants were females (62.4% versus 57.6%), and females had more AEFI compared with males. Also, among the survey participants, the majority (39.8%) were 20–30 years old, and a smaller number (8.4%) were above 50 years [7,10,11,18]. About 30% (96) of the study participants had comorbidities. In previous studies on AEFI in India, 34.1% of the participants were found to have comorbidities [7]. Also, comorbidities such as diabetes and hypertension topped the list. Our findings coincide with previous studies [7,11,12].

In this study, more participants received Covishield™ (77.9% versus 22.1%). Previous studies also had more participants who received Covishield™. This may be because of the fact that Covishield™ was available at many centers in India compared with Covaxin™ [7]. Of the participants, 5.9% (19) were diagnosed with COVID-19 post-vaccination. Among them, 15.8% (5) required hospitalization, with 10.5% (2) of them requiring oxygen. A survey conducted at Bangladesh found that below 10% (8.5%) of the participants were diagnosed with COVID-19 post-vaccination. Our data thus coincides with the study [12].

In this study, AEFIs were observed more following the first dose of both vaccines compared with the second dose. The results are similar to previous studies [7,10]. Also, in this study, there was a significant increase in the number of participants who experienced general AEFI following the first dose of Covishield™ as compared with Covaxin™. Till date, there are no comparative studies of AEFIs of these two vaccines. In this study, also, data is based on reporting by participants and in a specific population. Hence, generalized conclusions cannot be drawn. Also, any investigations into the role of active ingredients toward AEFIs are beyond the scope of this study.

Regarding AEFIs, <1% of the participants (0.3%) reported immediate hypersensitivity reaction, and the common localized reactions were pain (59%) and swelling (12.4%). This is similar to previous studies. Also, pain at the site of injection was the most commonly reported adverse event in clinical trials [12,18-20]. The most common systemic reactions were generalized weakness, fever, headache, chills, and dizziness after both first and second doses. Koebner phenomenon was reported by one vaccine recipient. The recipient has a known case of psoriasis. There was appearance of new psoriatic skin lesions at previously unaffected sites due to the cutaneous trauma, and it required medical attention. There are other case reports of skin manifestations after COVID-19 vaccination, including psoriasis flare up. The subjects, however, received their second doses as the reactions were mild and resolved with local medications [21,22].

In the study, the majority of the participants (71%) with AEFIs resorted to tablet paracetamol (500/650 mg) for their symptoms. Out of 67.4% (217) participants who had AEFI, 19.8% (43) reported to the doctor, 3.7%...
(8) reported to PvPI, and 76.5% (166) mentioned that they did not report their reaction. It is worthwhile to note that none of them reported through CoWIN. Also, the majority of participants did not report their reaction. Our results coincide with a previous study that also detected low reporting and that 74.66% of the subjects were not aware of adverse event reporting [23]. Therefore, it is important to first make vaccine recipients aware of AEFI reporting and encourage them to report through CoWIN. This is required as our experience is new with COVID-19. AEFIs had a probable association as per WHO scale. This coincides with previous literature [24].

This study was conducted in participants who received the questionnaire and volunteered to respond. Although it was conducted at the community level, we could have possibly skipped those hospitalized or experiencing serious AEFIs. Also, this was conducted on residents of housing complexes. The information that we acquired was based on subjective responses from the population rather than actual clinical assessment. The age range of the respondents was relatively wide, but it did not cover pediatric population as vaccination for COVID-19 was not available below 18 years. Very recently, the Government of India opened up vaccination of children above 15 years. Thus, a long-term study including pediatric population and various sociodemographic profiles of the community will draw more light on long-term AEFIs, if any, of COVID-19 vaccination.

Conclusions

Our study confirmed the facts available from clinical trial data that available COVID-19 vaccines under EUA are safe. AEFIs were more observed in females, and there were no significant differences in AEFIs between first and second doses and between Covishield™ and Covaxin™.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. The institutional ethics committee of Vydehi Institute of Medical Sciences and Research Centre issued approval VIEC/2021/APP/009.

Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue.

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that they have no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. World Health Organization: Vaccine safety basics e-learning manual. (2021). Accessed: June 30, 2021: https://vaccine-safety-training.org/overview-and-outcomes-3.html.

2. Thigajaran R: Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust. BML. 2021, 372:n196. 10.1136/bmj.n196

3. Pandey A, Sah P, Moghadas SM, Mandal S, Banerjee S, Hotze PJ, Galvani AP: Challenges facing COVID-19 vaccination in India: lessons from the initial vaccine rollout. J Glob Health. 2021, 11:03083. 10.7189/jogh.11.03083

4. Ministry of Health and Family Welfare: COVID-19 vaccines operational guidelines. (2021). Accessed: June 30, 2021: https://main.mohfw.gov.in/newshighlights-31.

5. Revised AEFI guidelines: executive summary. (2021). Accessed: June 30, 2021: https://main.mohfw.gov.in/sites/default/files/Revised%20AEFI%20Guidelines%20Executive%20Summary.pdf.

6. Prakash J, Sachdeva R, Shrivastava TP, et al.: Adverse event reporting tools and regulatory measures in India through outcome of pharmacovigilance programme of India. Indian J Pharmacol. 2021, 53:143-52.

7. Konda VC, Gokul T, Poojitha M, Rao KU: Adverse events following immunization to COVID-19 vaccines in a tertiary care hospital - a descriptive study. Biomed Pharmacol J. 2021, 14:10.15945/bpj/14112

8. Word Health Organization: COVID-19 vaccines: Safety surveillance manual: Establishing surveillance systems in countries using COVID-19 vaccines. (2021). Accessed: July 10, 2021: https://www.who.int/docs/default-source/covid-19-vaccines-safety-surveillance-manual/covid19vaccines_manual_surveilla...}

9. Kaur RJ, Dutta S, Bhardwaj P, et al.: Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021, 1-15. 10.1007/s12291-021-00969-9

10. Basavaraja CK, Sebastian J, Ravi MD, John SB: Adverse events following COVID-19 vaccination: first 90 days of experience from a tertiary care teaching hospital in South India. Ther Adv Vaccines Immunother. 2021, 9:25151355211055835. 10.1177/25151355211055835

11. Mohammed RA, Garout RM, Wahid S, Ayub F, Firas ZinAlddin LM, Sultan I: A survey on the side effects of Pfizer/BionTech COVID-19 vaccine among vaccinated adults in Saudi Arabia. Cureus. 2021, 13:e19222. 10.7759/cureus.19222

12. Jahann N, Rahman FI, Saha P, et al.: Side effects following administration of the first dose of Oxford-AstraZeneca’s Covishield vaccine in Bangladesh: a cross-sectional study. Infect Dis Rep. 2021, 13:888-901. 10.3390/idr13040080

13. Klein NP, Lewis N, Goddard K, et al.: Surveillance for adverse events after COVID-19 mRNA vaccination. JAMA. 2021, 326:1590-9. 10.1001/jama.2021.15072
14. Wu Q, Dudley MZ, Chen X, et al.: Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021, 19:173. 10.1186/s12916-021-02059-5
15. Jeon M, Kim J, Oh CE, Lee JY: Adverse events following immunization associated with coronavirus disease 2019 vaccination reported in the mobile vaccine adverse events reporting system. J Korean Med Sci. 2021, 36:e14. 10.3346/jkms.2021.36.e114
16. Immunization Action Coalition (IAC): Vaccine information for health care professionals. (2021). Accessed: June 10, 2021: https://www.immunize.org.
17. World Health Organization: Causality assessment of adverse event following immunization (AEFI). (2021). Accessed: August 13, 2021: https://www.who.int/vaccine_safety/publications/aefi_manual.pdf.
18. Suhagiya P, Hakim J, Athmakuri D, Kuracha M, Chander T: Surveillance of adverse events following immunization (AEFI) - post COVID 19 vaccination. Indian J Immunol Respir Med. 2021, 6:178-82. 10.18231/j.ijirm.2021.039
19. Ella R, Reddy S, Jogdand H, et al.: Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021, 21:950-61. 10.1016/S1473-3099(21)00079-0
20. Sachdev SS, Chettiankandy TJ, Adhane YB, Sardar MA, Yaduanshi K: Survey on individual experiences after first dose of COVID-19 vaccination amongst Indian oral health care personnel. J Community Health Manag. 2021, 8:119-23. 10.18231/j.jchm.2021.027
21. Piccolo V, Mazzatenta C, Bassi A, Argenziano G, Cutrone M, Grimalt R, Russo T: COVID vaccine-induced lichen planus on areas previously affected by vitiligo. J Eur Acad Dermatol Venereol. 2022, 36:e28-30. 10.1111/jdv.17687
22. Fang WC, Chiu LW, Hu SC: Psoriasis exacerbation after first dose of AstraZeneca coronavirus disease 2019 vaccine. J Dermatol. 2021, 48:e566-7. 10.1111/1346-8138.16157
23. Rajpurohit S, Suva M, Rajpurohit H, Singh Y, Boda P: A retrospective observational survey of adverse events following immunization comparing tolerability of covishield and covaxin vaccines in the real world. JPADR. 2021, 2:20-5. 10.53411/jpadr.2021.2.5.5
24. Kaur U, Ojha B, Pathak BK, et al.: A prospective observational safety study on ChAdOx1 nCoV-19 corona virus vaccine (recombinant) use in healthcare workers- first results from India. EClinicalMedicine. 2021, 38:101038. 10.1016/j.eclinm.2021.101038